ACIU
AC Immune SA

3,772
Mkt Cap
$328.11M
Volume
265,424.00
52W High
$4.00
52W Low
$1.43
PE Ratio
-3.70
ACIU Fundamentals
Price
$2.91
Prev Close
$3.12
Open
$3.15
50D MA
$3.09
Beta
0.98
Avg. Volume
450,123.52
EPS (Annual)
-$0.5799
P/B
3.50
Rev/Employee
$180,287.39
Loading...
Loading...
News
all
press releases
FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright
AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...
MarketBeat·12d ago
News Placeholder
More News
News Placeholder
FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs
AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...
MarketBeat·12d ago
News Placeholder
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·22d ago
News Placeholder
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·23d ago
News Placeholder
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
New Strong Sell Stocks for August 6th
ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.
Zacks·4mo ago
News Placeholder
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of -25.00% and -57.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago
News Placeholder
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago

Latest ACIU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.